INSR and lymphoma: The insulin receptor IGF-1R inhibitor BMS536924 was the only drug with a confirmed specific activity against Ba/F3 overexpressing BTKE41K-C481S over a large range of doses, but this was not confirmed in the lymphoma cell line TMD8 (Supplementary Figure S3B).